Guided by the clinical philosophy of full-lifecycle care covering neonatal interventions, core products include the Pul-Stent® Pulmonary Artery Stent and the PT-Valve® Transcatheter Pulmonary Valve. Pul-Stent® is the world’s first dedicated stent approved for pulmonary artery stenosis treatment. The PT-Valve® is a domestically developed transcatheter pulmonary valve with China’s largest implantation volume and broadest indication coverage. Supported under a national key R&D program of the 13th Five-Year Plan (MOST), this product has entered the NMPA’s Special Approval Channel for Innovative Medical Devices and is now under technical review. It is expected to obtain marketing approval by the end of 2026, making it the fourth commercially launched transcatheter pulmonary valve worldwide. This product line addresses long-term clinical management demands for complex congenital heart defects, delivers distinct clinical value, and boasts steadily expanding market potential.
